Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Abata Therapeutics.

    Client Virtual Booth

    ABATA THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Abata Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Cambridge, MA US
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://abatatx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/abata-therapeutics/about/
    Twitter
    Twitter
    https://twitter.com/AbataTx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatment of Type 1 Diabetes

    Details:

    ABA-201 is Abata’s autologous Treg therapy in development for the treatment of T1D. It targets T1D patients who have remaining beta cell function and a specific HLA genetic haplotype.


    Lead Product(s): ABA-201

    Therapeutic Area: Endocrinology Product Name: ABA-201

    Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 24, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Abata Therapeutics Launches to Usher in New Era of Cell Therapy Using Targeted Regulatory T Cells

    Details:

    Abata’s autologous Treg cell therapies are engineered to express T cell receptors (TCRs) that recognize antigens present in tissue where an autoimmune response has been triggered.


    Lead Product(s): Autologous Treg Cell Therapies

    Therapeutic Area: Immunology Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Third Rock Ventures

    Deal Size: $95.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing June 23, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    minakem-m-2024-05-27

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search